Associated Papers
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.
Medina PP et al.
Human Mutation, 2008
Select a paper to view details